Biosimilars, Thursday 1 March 2018


Organiser's Welcome Remarks

Alfred Scheidegger

Chair's Opening Remarks

Alfred Scheidegger, Chief Executive Officer, Nextech Invest

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Speed Networking


Exhibition Visit & Networking Refreshments

Biosimilars in Asia


Chair's Opening Remarks

Joe Zhou

mAb Industry in China: Biosimilars vs. Innovative Biologics

Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.
1.        Landscape changes of mAb therapeutics
2.        New targets and process/manufacturing innovation
3.        Key consideration of mAb industry in China
4.        Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market
Forrest Hu

Challenges & strategies for biosimilar business in emerging markets

    style="font-size: 10.0pt;">
  •     Overview of current situation  and Challenges  in Emerging Market;
  •     Strategies in exploring different territories in Asia
  •     Overview of New guideline for biosimilar in China  
Kaustubh Berde

Cost vs quality: What’s the best strategies for Asia biosimilars market?

  • Exploring strategies in addressing differences in biosimilar regulation
  • Case study: Regulated vs unregulated biosimilars market in Asia
  • Overcoming challenges in tech know-how and different approaches and understanding of concepts by regulatory agencies
Kaustubh Berde, Vice President for International Business : Emerging Markets, Wockhardt Limited

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Avoiding delays to the clinic

John Moore, Director of Global Clinical Business Development, Vetter Pharma International

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: Why don’t we have an ICI in breast cancer – yet?

Stefan Gluck, Vice President of Global Medical Affairs, Celgene

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: Preparation steps to brace healthcare & pharma digital transformation

round tables

Table 9: Reconciling the diversified pharma regulations in Asia


Exhibition Visit & Networking Lunch


Chair's Opening Remarks


Choosing the right Asian country for your biosimilar trials

  • Exploring solutions for overcoming the unique challenges in running clinical trials for biosimilars in Asia
  • Overcoming knowledge gaps among investigators when it comes to handling biosimilars
  • Crafting education and awareness campaigns to promote trial participation interest
Dinesh Kundu

India’s Biosimilar clinical trials landscape: What do you need to know?

Regulation was previously a big issue in India but the country is making a comeback as a biosimilars trial destination. Join this session to learn more about the latest regulations and key requirements for conducting biosimilar trials in India. Topics include quality compliance in running biosimilar trials in India.
Sujay Singh

Moving from generic antibody supplier to biosimilars developers: Key insights learnt from development to biosimilars productions

    style="font-size: 10.0pt;">
  •     Sharing of company background and insights learnt moving from antibodies supplier to biosimilars developer 
  •     Discussing strategies to maintain product quality in upscaling biosimilars
  •     Exploring key assays techniques and development for biosimilars testing

Exhibition Visit & Networking Refreshments

Biosimilars Development


Solomon Alva

Manufacturing strategies for Biosimilar: A case of continuous capture

  • A case study of continuous capture process development
  • Key strategies in moving from batch to a continuous process
  • Integrating continuous cell culture and purification
Samir Varma

Fully continuous biosimilar manufacturing framework: A case study

  • Strategies in establishing a fully continuous biosimilar framework
  • Overcoming challenges connecting upstream and downstream sections in building continuous processing system
  • Case study
Panel discussion

What’s next in greener, more efficient biomanufacturing?

After years of discussion, the industry is moving from traditional stainless steel based production to single use, continuous processing. In this exciting time, what is the next innovation which we can expect to create greener, more efficient methods for biologics production? 

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 19/Jan/18 08:15

Biosimilars, Friday 2 March 2018


Organiser's Welcome Remarks


Chair's Opening Remarks

Disruption & Digitalisation

Tony Liu

Shifting paradigm of the advanced therapy landscape in Asia

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. 
Antonio Lee

Innovation beyond limit: How do we conquer incurable diseases and create new history

Advancement in research helps to push the limitation of treatment paradigm to attempt curing currently incurable diseases. Innovative therapeutic solutions however is often not sufficient without a strong team to help with commercialisation. In this presentation, Antonio will share about the overall landscape in Asia stem cell therapy, challenges in current landscape and opportunities ahead to achieve commercial excellence.  
Ivor Lim

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.

Exhibition Visit & Networking Refreshments

Manufacturing: Upscaling


Chair's Opening Remarks

Jacob Jensen

Use of Biocapacitance probes for optimized process control at Large-Scale Manufacturing

Hung Fai Poon

Platform tech development for biosimilar upscaling

  • Discover strategies to move candidate molecules through development
  • Building consistent, straightforward processes with low variability
  • Exploring the possibility of using single use, high throughput bioreactors in the upscaling process

Outsourcing biosimilar manufacturing as an alternative to successful upscaling processes

  • What are the deciding factors in choosing a partner for biosimilar manufacturing?
  • Cost vs quality: Deciding between a more affordable local partner and a costlier but more trustworthy international one
  • Case study in Asia

Exhibition Visit & Networking Lunch


Chair's Opening Remarks

Alfred Scheidegger

Global Immuno-Oncology Investment Trends & Opportunities

Alfred Scheidegger, Chief Executive Officer, Nextech Invest

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
Sebastian Sujka

AI in pharma: Using digital technology for disease prevention

Sebastian Sujka, CEO & Co-Founder, Xbird, Bayer’s Grants4Apps

Exhibition Visit & Networking Refreshments



Chair's Opening Remarks


Awareness campaigns and strategies to promote biosimilar adoption

  • Getting marketing authorisation is not enough, how do biosimilar companies convince providers to switch to more affordable yet less established biosimilar alternatives?
  • Exploring alternative strategies in developing vs developed markets
Establishing awareness campaigns for patients and prescribers

Building sustainable stakeholder relationship to encourage biosimilar adoption

  • Displaying product’s similarity in clinical performance, quality, and potency
  • Convincing authorities that the designed manufacturing process is well understood and robust
  • Marketing products at a lower price as compared to originator 

Physician and provider engagement to support biosimilar drugs administration

  • Strategies for implementing frameworks to promote biosimilar awareness
  • Crafting patient education and engagement programs in Asia
  • Exploring strategies to overcome delayed ADR effects

Adverse Drug Response reporting for biosimilar

  • Using post market data to identify immunogenicity of biosimilar drugs
  • Performing benefit-risk analysis to ensure drug safety
  • Collecting ADR in developing countries: How do we do it?

Close of Phar-East 2018

last published: 19/Jan/18 08:15